Public Employees Retirement System of Ohio purchased a new position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 7,376 shares of the biotechnology company's stock, valued at approximately $1,101,000.
Several other institutional investors have also recently added to or reduced their stakes in the stock. Westfield Capital Management Co. LP lifted its holdings in Ascendis Pharma A/S by 3.4% during the 3rd quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company's stock worth $766,523,000 after buying an additional 170,942 shares during the last quarter. Avoro Capital Advisors LLC lifted its stake in Ascendis Pharma A/S by 5.8% during the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company's stock worth $572,341,000 after purchasing an additional 229,995 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in Ascendis Pharma A/S by 6.8% in the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company's stock worth $625,075,000 after purchasing an additional 267,881 shares during the period. Massachusetts Financial Services Co. MA increased its stake in Ascendis Pharma A/S by 9.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company's stock valued at $278,760,000 after purchasing an additional 155,971 shares during the last quarter. Finally, Groupama Asset Managment bought a new stake in Ascendis Pharma A/S during the third quarter valued at $60,000.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on ASND shares. Wedbush reaffirmed an "outperform" rating and issued a $181.00 price target on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Stifel Nicolaus lifted their target price on Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a "buy" rating in a research note on Friday, November 15th. StockNews.com raised Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a report on Wednesday, November 20th. Bank of America raised their price target on Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a "buy" rating in a report on Monday, September 23rd. Finally, Oppenheimer lowered their price objective on Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating for the company in a research note on Friday, November 15th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $191.77.
Read Our Latest Research Report on ASND
Ascendis Pharma A/S Stock Performance
Shares of ASND stock traded down $1.36 during midday trading on Friday, reaching $136.38. 632,702 shares of the company were exchanged, compared to its average volume of 451,274. The company's 50 day moving average price is $129.54 and its two-hundred day moving average price is $132.81. The company has a market cap of $8.27 billion, a P/E ratio of -16.88 and a beta of 0.67. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $161.00.
Ascendis Pharma A/S Company Profile
(
Free Report)
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
See Also
Before you consider Ascendis Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.
While Ascendis Pharma A/S currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.